Revium Rx. (RVRC) — SEC Filings
Revium Rx. (RVRC) — 4 SEC filings. Latest: S-1/A (Dec 12, 2025). Sentiment: bearish. Includes 3 S-1/A, 1 S-1. Overall sentiment: bearish.
Overview
Revium Rx. (RVRC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1/A filed on Dec 12, 2025: Revium Rx. (RVRC) filed an S-1/A on December 12, 2025, detailing a self-underwritten initial public offering (IPO) of up to 1,562,500 Units at a fixed price of $3.20 per Unit. Each Unit comprises two shares of common stock and one warrant to purchase one share of common stock at an exercise price of
Sentiment Summary
Across 4 filings, the sentiment breakdown is: 3 bearish, 1 neutral. The dominant filing sentiment for Revium Rx. is bearish.
Filing Type Overview
Revium Rx. (RVRC) has filed 3 S-1/A, 1 S-1 with the SEC between Feb 2025 to Dec 2025.
Recent SEC Filings (4)
| Date | Form | Description | Risk |
|---|---|---|---|
| Dec 12, 2025 | S-1/A | Revium Rx. Launches Dual Offering: IPO at $3.20, Resale at $1.00 | high |
| Oct 3, 2025 | S-1/A | Revium Rx. Launches Dual IPO, Resale Offerings Amid Price Disparity | high |
| Aug 13, 2025 | S-1/A | Revium Rx Launches IPO, Selling Stockholders Eye Massive Resale | high |
| Feb 14, 2025 | S-1 | Revium Rx. Files S-1 for Public Offering | medium |
Risk Profile
Risk Assessment: Of RVRC's 4 recent filings, 3 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Key Executives
- Amir Avraham
- David Aboudi, Esq.
- David Akunis
- Mark Crone
- David Aboudi
- Eleanor Osmanoff
Industry Context
The pharmaceutical and biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Revium Rx. operate in a competitive landscape where innovation, intellectual property, and successful clinical trials are critical for market entry and success. The industry is also subject to evolving healthcare policies and reimbursement landscapes.
Top Tags
IPO (3) · S-1/A (3) · OTC Markets (3) · Dilution Risk (2) · Biotechnology (2) · Dual Offering (1) · Capital Raise (1) · Resale Offering (1) · Antimicrobial Resistance (1) · High Risk (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Units offered in Primary Offering | 1,562,500 | Each Unit consists of two shares of common stock and one warrant |
| Price per Unit in Primary Offering | $3.20 | Fixed offering price for new investors |
| Shares offered in Resale Offering | 37,625,790 | Offered by Selling Stockholders |
| Price per share in Resale Offering | $1.00 | Fixed price for selling stockholders until OTCQB or national exchange listing |
| Last reported sale price on OTC Market | $0.52 | As of December 12, 2025, significantly below offering prices |
| Exercise price of IPO Warrants | $2.40 | Warrants included in the Primary Offering Units |
| Years | 3 | Expiration period for IPO Warrants |
| Days | 365 | Duration of the Primary Offering |
| Primary Offering Unit Price | $3.20 | Fixed offering price per Unit in the self-underwritten IPO |
| Units Offered in Primary Offering | 1,562,500 | Maximum number of Units to be sold by the Company |
| Resale Offering Share Price | $1.00 | Fixed price per share for Selling Stockholders until OTCQB/QX listing |
| Shares Offered in Resale Offering | 37,625,790 | Maximum number of Common Stock shares to be sold by Selling Stockholders |
| Last Reported Sale Price (OTC Market) | $0.52 | Revium Rx. Common Stock price on OTC Market as of October 2, 2025 |
| IPO Warrant Exercise Price | $2.40 | Exercise price per share for warrants included in Primary Offering Units |
| Common Stock in Primary Offering Units | 3,125,000 | Total shares of Common Stock included in the 1,562,500 Units |
Frequently Asked Questions
What are the latest SEC filings for Revium Rx. (RVRC)?
Revium Rx. has 4 recent SEC filings from Feb 2025 to Dec 2025, including 3 S-1/A, 1 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RVRC filings?
Across 4 filings, the sentiment breakdown is: 3 bearish, 1 neutral. The dominant sentiment is bearish.
Where can I find Revium Rx. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Revium Rx. (RVRC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Revium Rx.?
Financial highlights for Revium Rx. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for RVRC?
The investment thesis for RVRC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Revium Rx.?
Key executives identified across Revium Rx.'s filings include Amir Avraham, David Aboudi, Esq., David Akunis, Mark Crone, David Aboudi and 1 others.
What are the main risk factors for Revium Rx. stock?
Of RVRC's 4 assessed filings, 3 were flagged high-risk, 1 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Revium Rx.?
Forward guidance and predictions for Revium Rx. are extracted from SEC filings as they are enriched.